BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug
Study shows efficacy and safety of oral antibiotic therapy in the form of pills for Staphylococcus aureus bloodstream infections. Currently, infusions are the standard treatment / published in ‘The
Tuberculosis is currently the infectious disease that causes the most deaths worldwide. Of particular concern is the increasing emergence of multidrug-resistant tuberculosis bacteria, particularly in
Bacteria that are resistant to broad-spectrum antibiotics from the carbapenem group are increasingly posing major problems for healthcare systems worldwide. They can cause serious infections and
Darobactin is a promising candidate for the development of new, resistance-breaking antibiotics, as it has an exceptional mechanism of action and a broad spectrum of activity. In a recent study, DZIF
INCATE, the INCubator for Antibacterial Therapies in Europe, and BIOASTER, the French Technology Research Institute, have announced this week the beginning of a new partnership that aims to improve
From 18 to 24 November, the “World AMR Awareness Week” (WAAW), a global campaign proclaimed by WHO, aims to draw attention to the near-pandemic rise in infections caused by resistant microbial
Despite decades of research, there is still no vaccine that protects against HIV infection. It is currently assumed, however, that such a vaccine can only be effective if it also produces so-called
With one of the highest tuberculosis (TB) incidences (368 cases/100,000 population) in the African region, Mozambique is particularly affected by the TB epidemic. Drug-resistant TB is also a major
Please use the foto only in connection with the press release.
The German Center for Infection Research (DZIF) and the French National Research Agency for HIV, viral hepatitis and emerging infectious diseases (ANRS | MIE)announced their commitment to
